TY - JOUR
T1 - Incorporation of cis-9,trans-11 or trans-10,cis-12 conjugated linoleic acid into plasma and cellular lipids in healthy men
AU - Burdge, Graham C
AU - Lupoli, Berit
AU - Russell, Jennifer J
AU - Tricon, Sabine
AU - Kew, Samantha
AU - Banerjee, Tapati
AU - Shingfield, Kevin J
AU - Beever, David E
AU - Grimble, Robert F
AU - Williams, Christine M
AU - Yaqoob, Parveen
AU - Calder, Philip C
PY - 2004/4
Y1 - 2004/4
N2 - This study investigated the incorporation of cis-9,trans-11 conjugated linoleic acid (c9,t11 CLA) and trans-10,cis-12-CLA (t10,c12 CLA) into plasma and peripheral blood mononuclear cell (PBMC) lipids when consumed as supplements highly enriched in these isomers. Healthy men (n = 49, age 31 +/- 8 years) consumed one, two, and four capsules containing approximately 600 mg of either c9,t11 CLA or t10,c12 CLA per capsule for sequential 8 week periods followed by a 6 week washout before consuming the alternative isomer. Both isomers were incorporated in a dose-dependent manner into plasma phosphatidylcholine (PC) (c9,t11 CLA r = 0.779, t10,c12 CLA r = 0.738; P <0.0001) and cholesteryl ester (CE) (c9,t11 CLA r = 0.706, t10,c12 CLA r = 0.788; P <0.0001). Only t10,c12 CLA was enriched in plasma nonesterified fatty acids. Both c9,t11 CLA and t10,c12 CLA were incorporated linearly into PBMC total lipids (r = 0.285 and r = 0.273, respectively; P <0.0005). The highest concentrations of c9,t11 CLA and t10,c12 CLA in PBMC lipids were 3- to 4-fold lower than those in plasma PC and CE. These data suggest that the level of intake is a major determinant of plasma and PBMC CLA content, although PBMCs appear to incorporate both CLA isomers less readily.
AB - This study investigated the incorporation of cis-9,trans-11 conjugated linoleic acid (c9,t11 CLA) and trans-10,cis-12-CLA (t10,c12 CLA) into plasma and peripheral blood mononuclear cell (PBMC) lipids when consumed as supplements highly enriched in these isomers. Healthy men (n = 49, age 31 +/- 8 years) consumed one, two, and four capsules containing approximately 600 mg of either c9,t11 CLA or t10,c12 CLA per capsule for sequential 8 week periods followed by a 6 week washout before consuming the alternative isomer. Both isomers were incorporated in a dose-dependent manner into plasma phosphatidylcholine (PC) (c9,t11 CLA r = 0.779, t10,c12 CLA r = 0.738; P <0.0001) and cholesteryl ester (CE) (c9,t11 CLA r = 0.706, t10,c12 CLA r = 0.788; P <0.0001). Only t10,c12 CLA was enriched in plasma nonesterified fatty acids. Both c9,t11 CLA and t10,c12 CLA were incorporated linearly into PBMC total lipids (r = 0.285 and r = 0.273, respectively; P <0.0005). The highest concentrations of c9,t11 CLA and t10,c12 CLA in PBMC lipids were 3- to 4-fold lower than those in plasma PC and CE. These data suggest that the level of intake is a major determinant of plasma and PBMC CLA content, although PBMCs appear to incorporate both CLA isomers less readily.
KW - Adult
KW - Cholesterol Esters
KW - Cross-Over Studies
KW - Dietary Supplements
KW - Double-Blind Method
KW - Fatty Acids
KW - Humans
KW - Leukocytes, Mononuclear
KW - Linoleic Acids
KW - Linoleic Acids, Conjugated
KW - Lipids
KW - Male
KW - Phosphatidylcholines
UR - http://hdl.handle.net/2160/12786
U2 - 10.1194/jlr.M300447-JLR200
DO - 10.1194/jlr.M300447-JLR200
M3 - Article
C2 - 14754909
SN - 0022-2275
VL - 45
SP - 736
EP - 741
JO - Journal of Lipid Research
JF - Journal of Lipid Research
IS - 4
ER -